| Balance Sheets | 2025-06-30 | |||
|---|---|---|---|---|
| Property and equipment, net | 462 | |||
| Restricted cash | 0 | |||
| Prepaid expenses and other current assets | 5,119 | |||
| Marketable securities | 371,066 | |||
| Cash and cash equivalents | 119,437 | |||
| Total current assets | 495,622 | |||
| Other long-term assets | 7,239 | |||
| Operating lease right-of-use assets | 564 | |||
| Total assets | 503,887 | |||
| Accrued expenses and other current liabilities | 12,860 | |||
| Accounts payable | 2,351 | |||
| Total current liabilities | 15,211 | |||
| Long-term liabilities | 204 | |||
| Total liabilities | 15,415 | |||
| Accumulated deficit | -297,351 | |||
| Common stock, par value 0.001 authorized shares - 100,000,000 issued and outstanding shares - 59,226,171 and 48,936,459 at june 30, 2025 and december 31, 2024, respectively | 59 | |||
| Additional paid-in capital | 785,941 | |||
| Accumulated other comprehensive (loss) income | -177 | |||
| Total stockholders' equity | 488,472 | |||
| Total liabilities and stockholders' equity | 503,887 | |||
Enliven Therapeutics, Inc. (IMRA)
Enliven Therapeutics, Inc. (IMRA)